What conditions is Rinvoq (upadacitinib) indicated for?

What is Rinvoq (Upadacitinib) Used For?

Rinvoq (upadacitinib) is a JAK inhibitor approved for treating multiple immune-mediated inflammatory diseases in adults and select pediatric populations, specifically after inadequate response or intolerance to TNF blockers in most indications. 1

FDA-Approved Indications

Rheumatologic Conditions

• Rheumatoid arthritis (RA): Approved for adults with moderately to severely active disease who have failed or cannot tolerate one or more TNF blockers, dosed at 15 mg once daily 1, 2
• Psoriatic arthritis (PsA): Approved for adults and pediatric patients ≥2 years with active disease after inadequate response or intolerance to TNF blockers 1, 2
• Ankylosing spondylitis (AS): Approved for adults with active disease who have failed or cannot tolerate TNF blockers, dosed at 15 mg once daily 1, 2
• Non-radiographic axial spondyloarthritis (nr-axSpA): Approved for adults with objective signs of inflammation after inadequate response or intolerance to TNF blockers 1, 2
• Polyarticular juvenile idiopathic arthritis (pJIA): Approved for patients ≥2 years with active disease after TNF blocker failure or intolerance 1, 2

Dermatologic Conditions

• Atopic dermatitis (AD): Approved for adults and pediatric patients ≥12 years with refractory, moderate to severe disease inadequately controlled by other systemic drugs (including biologics) or when those therapies are inadvisable, dosed at 15 mg or 30 mg once daily 1, 3

Gastrointestinal Conditions

• Ulcerative colitis (UC): Approved for adults with moderately to severely active disease after inadequate response or intolerance to TNF blockers, using 45 mg once daily for induction (8-16 weeks) followed by 15 mg or 30 mg once daily for maintenance 1, 3
• Crohn's disease (CD): Approved for adults with moderately to severely active disease after inadequate response or intolerance to TNF blockers, typically 45 mg for induction followed by 15 mg or 30 mg for maintenance 1, 2, 4

Mechanism and Positioning

Upadacitinib is a selective JAK1 inhibitor that blocks cytokine signaling pathways central to inflammatory disease pathogenesis. 5 It represents the first oral agent proven effective for both inducing and maintaining remission in Crohn's disease. 4

Key Positioning Principles

• Not recommended as first-line therapy: FDA and European Medicines Agency restrict JAK inhibitors to patients who have failed or are intolerant to TNF antagonists 4, 3
• Avoid combination therapy: Not recommended with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (azathioprine, cyclosporine) across all indications 1
• Higher efficacy option: Considered a "HIGHER efficacy medication" by the American Gastroenterological Association for ulcerative colitis 3

Critical Safety Warnings (FDA Black Box)

Absolute Contraindications and High-Risk Situations

• Active serious infections: Interrupt treatment until infection is controlled 1
• Pregnancy and lactation: Contraindicated due to animal teratogenicity data; women of childbearing age require effective contraception 2, 3
• Severe hepatic disease (Child-Pugh C): Not recommended 3
• Severe renal impairment (CrCl <15 mL/min): Contraindicated for upadacitinib; maximum 15 mg daily if CrCl <30 mL/min 2, 3
• Live vaccines: Contraindicated during treatment 2

Major Cardiovascular and Thrombotic Risks

• History of venous thromboembolism (VTE): Dose-dependent risk of pulmonary embolism and deep vein thrombosis, particularly in patients with VTE risk factors 2, 1
• Major adverse cardiovascular events (MACE): Higher rates observed with JAK inhibitors versus TNF blockers in RA patients, especially in those ≥65 years with cardiovascular risk factors 1, 3
• Age ≥65 years with cardiovascular risk factors: Avoid unless no suitable alternatives exist 3
• Current or previous long-term smokers: Increased risk for adverse cardiovascular outcomes 3

Malignancy Concerns

• History of malignancy: Added to 2024 recommendations given numerical imbalance in some malignancies versus TNF blockers, particularly lung cancer in smokers 2, 1
• Non-melanoma skin cancer (NMSC): Increased risk documented in registries; perform baseline skin checks for at-risk patients 2

Infectious Disease Risks

• Tuberculosis: Test for latent TB before and during therapy; treat latent TB prior to initiating upadacitinib 1, 4
• Viral hepatitis: Screen for hepatitis B and C before treatment 4, 3
• Herpes zoster: Significantly increased risk (4.0-7.2% on maintenance therapy); consider recombinant zoster vaccine (Shingrix) before initiating treatment 4, 6

Mandatory Pre-Treatment Screening

Before initiating upadacitinib, complete the following assessments: 4, 3

• Update all immunizations (especially recombinant zoster vaccine)
• Screen for active and latent tuberculosis
• Test for viral hepatitis (HBV, HCV)
• Check pregnancy status in women of childbearing age
• Obtain baseline complete blood count with differential
• Check liver enzymes and renal function
• Assess lipid panel

Laboratory Monitoring Requirements

Avoid Initiation or Interrupt Treatment If:

• Absolute lymphocyte count <500 cells/mm³ 1, 4
• Absolute neutrophil count <1000 cells/mm³ 1, 4
• Hemoglobin <8 g/dL 1

Ongoing Monitoring Schedule

• CBC with differential and comprehensive metabolic panel: At baseline, 4-8 weeks after starting, then every 3 months 3
• Lipids: At baseline, 4 weeks for some formulations or 12 weeks for upadacitinib, then annually 3
• Monitor for signs of infection, particularly herpes zoster, and counsel on VTE warning signs 3

Special Population Dosing Adjustments

• Severe renal impairment (CrCl <30 mL/min): Maximum 15 mg daily 3
• Age ≥75 years: Consider dose reduction to 15 mg daily 3
• Hepatic impairment (Child-Pugh A/B): No dose adjustment needed; avoid in Child-Pugh C 2, 3

Common Pitfalls to Avoid

• Do not use as first-line therapy in biologic-naïve patients when TNF inhibitors remain viable options, especially in patients ≥65 years with cardiovascular risk factors 4, 3
• Do not ignore smoking status: Current or past smokers with cardiac disease represent the highest-risk population for adverse cardiovascular outcomes 3
• Do not combine with other immunosuppressants: Avoid use with other JAK inhibitors, biologics, or potent immunosuppressants across all indications 1
• Do not overlook VTE risk factors: Enhanced monitoring required for patients with history of thromboembolism, age >65 years, or cardiovascular disease 2, 3